Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor.
The combined use of retinoic acid and chemotherapy has led to an important improvement of cure rates in acute promyelocytic leukemia. Retinoic acid forces terminal maturation of the malignant cells and this application represents the first generally accepted differentiation-based therapy in leukemia. Unfortunately, similar approaches have failed in other types of hematological malignancies suggesting that the applicability is limited to this specific subgroup of patients. This has been endorsed by the notorious lack of response in acute promyelocytic leukemia bearing the variant t(11;17) translocation. Based on the reported synergistic effects of retinoic acid and the hematopoietic growth factor granulocyte colony-stimulating factor (G-CSF), we studied maturation of t(11;17) positive leukemia cells using several combinations of retinoic acid and growth factors. In cultures with retinoic acid or G-CSF the leukemic cells did not differentiate into mature granulocytes, but striking granulocytic differentiation occurred with the combination of both agents. At relapse, the patient was treated with retinoic acid and G-CSF before reinduction chemotherapy. With retinoic acid and G-CSF treatment alone, complete granulocytic maturation of the leukemic cells occurred in vivo, followed by a complete cytogenetical and hematological remission. Bone marrow and blood became negative in fluorescense in situ hybridization analysis and semi-quantitative polymerase chain reaction showed a profound reduction of promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion transcripts. This shows that t(11;17) positive leukemia cells are not intrinsically resistant to retinoic acid, provided that the proper costimulus is administered. These observations may encourage the investigation of combinations of all-trans retinoic acid and hematopoietic growth factors in other types of leukemia.
Jansen
J H
JH
Institute of Hematology, the Department of Clinical Genetics, Erasmus University Rotterdam, Rotterdam, The Netherlands. jansen@hema.fgg.eur.nl
de Ridder
M C
MC
Geertsma
W M
WM
Erpelinck
C A
CA
van Lom
K
K
Smit
E M
EM
Slater
R
R
vd Reijden
B A
BA
de Greef
G E
GE
Sonneveld
P
P
Löwenberg
B
B
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002880:Chromosomes, Human, Pair 11; D002886:Chromosomes, Human, Pair 17; D004359:Drug Therapy, Combination; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D008297:Male; D012074:Remission Induction; D014178:Translocation, Genetic; D014212:Tretinoin / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor; D014212:Tretinoin